Dragonfly Therapeutics Initiates Phase 1/1b Study of its IL-2 Immunotherapy in Patients with Advanced Solid Tumors

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Dragonfly-Phase1/1b

More Like This

PR Newswire associated0

Dragonfly Therapeutics to Present Preclinical Data on Clinical-Stage DF6215, its Engineered IL-2R alpha-active Agonist, and DF9001, its EGFR-targeting TriNKET®, at the Society for Immunotherapy of Cancer (SITC) Annual Conference

PR Newswire associated0

Dragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303

PR Newswire associated0

Dragonfly Therapeutics, Inc. Announces Clinical Collaboration to Evaluate DF9001, an EGFR targeting TriNKET®, in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors

PR Newswire associated0

Dragonfly Announces Clinical Collaboration Exploring Combinations of Dragonfly's DF1001 HER-2 TriNKET® with Gilead's Trodelvy® in two Cancer Indications

Delta-Fly Pharma Inc.: Update for Expanded Phase I Study of DFP-14927

Delta-Fly Pharma Inc.: Notice of Initiation of Phase III Pivotal comparative clinical trial of DFP-14323

Delta-Fly Pharma Inc.: Update on the Interim Analysis Status of Phase III Study of DFP-10917 in the patients with R/R AML

Delta-Fly Pharma Inc.: Abstracts submission for Phase I Clinical Trial of DFP-14927 to 2024 ASCO annual meeting